End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 SEK | -0.23% | +0.92% | +31.14% |
Apr. 22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
Feb. 13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
Business Summary
Number of employees: 19
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug
78.4
%
| 135 | 33.0 % | 204 | 78.4 % | +50.55% |
One-off Nature
21.6
%
| 274 | 67.0 % | 56 | 21.6 % | -79.54% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
62.6
%
| 410 | 100.0 % | 163 | 62.6 % | -60.28% |
Scandinavia
28.5
%
| - | - | 74 | 28.5 % | - |
Rest of Europe
8.9
%
| - | - | 23 | 8.9 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
Chief Operating Officer | 46 | - | |
Corporate Officer/Principal | 54 | 16-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 05-12-31 | |
Director/Board Member | 64 | 14-12-31 | |
Director/Board Member | 51 | 19-12-31 | |
Per Svangren
BRD | Director/Board Member | 51 | 20-12-31 |
Per Ollermark
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,063,610 | 29,063,610 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.14% | 118M | |
-26.47% | 11.95B | |
+12.44% | 6.36B | |
-27.83% | 6.27B | |
-10.37% | 6.12B | |
-2.48% | 4.75B | |
+64.00% | 4.58B | |
-6.67% | 3.84B | |
-10.84% | 3.51B | |
-7.26% | 3.1B |
- Stock Market
- Equities
- EQL Stock
- Company EQL Pharma AB